The therapeutic potential of CXCR4 antagonists in the treatment of HIV

Expert Opinion on Investigational Drugs

Volumn 12, Issue 2, 2003, Pages 185-195

  Fujii, Nobutaka ^a   Nakashima, Hideki ^b   Tamamura, Hirokazu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ALX40 4C; AMD3100; AntiHIV agents; Chemokine receptors; CXCR4 antagonists; T140; T22

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; [TYROSINE 5 12 LYSINE 7] POLYPHEMUSIN 2; ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; AMD 8664; ANTIRETROVIRUS AGENT; C 34; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; E 913; ENFUVIRTIDE; GLYCOPROTEIN GP 120; KRH 1120; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; RECEPTOR BLOCKING AGENT; SC 34; T 1249; T 140; T 22; TC 14012; TN 14003; TN 14012; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER HOMOGENATE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN DOMAIN; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; ANIMALS; ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTORS, CXCR4;

EID: 0037319360     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.2.185     Document Type: Review

References (65)

1. MITSUYA H, ERICKSON J: Drug development. A. Discovery and development of antiretroviral therapeutics for HIV infection. In: Textbook of AIDS Medicine. TC Merigan, JG Bartlett, D Bolognesi (Eds), Williams & Wilkins, Baltimore (1999):751-780.
2. FENG Y, BRODER CC, KENNEDY PE, BERGER EA: HIV-1 entry co-factor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 272:872-877.
3. DENG H, LIU R, ELLMEIER W et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 381:661-666.
4. DRAGIC T, LITWIN V, ALLAWAY GP et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 381:667-673.
5. ALKHATIB G, COMBADIERE C, BRODER CC et al.: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 272:1955-1958.
6. CHOE H, FARZAN M, SUN Y et al.: The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 85:1135-1148.
7. DORANZ BJ, RUCKER J, YI Y et al.: A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 85:1149-1158.
8. CHAN DC, KIM PS: HIV entry and its inhibition. Cell (1998) 93:681-684.
9. MURAKAMI T, NAKAJIMA T, KOYANAGI Y et al.: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med. (1997) 186:1389-1393.
10. SCHOLS D, STRUYF S, VAN DAMME J, ESTE JA, HENSON G, DE CLERCQ E: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. (1997) 186:1383-1388.
11. DORANZ BJ, GROVIT-FERBAS K, SHARRON MP et al.: A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. (1997) 186:1395-1400.
12. 7]-polyphemusin II). Biochem Biophys. Res. Commun. (1992) 189:845-850.
13. NAKASHIMA H, MASUDA M, MURAKAMI T et al.: Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob. Agents Chemother. (1992) 36:1249-1255.
14. NAKAMURA T, FURUNAKA H, MIYATA T et al.: Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab (Tachypleus tridentatus). J. Biol. Chem. (1988) 263:16709-16713.
15. MIYATA T, TOKUNAGA F, YONEYA T et al.: Antimicrobial peptides, isolated from horseshoe crab hemocytes, tachyplesin II, and polyphemusins I and II: chemical structures and biological activity. J. Biochem. (1989) 106:663-668.
16. 7]-polyphemusin II), determined by nuclear magnetic resonance. Biochim. Biophys. Acta (1993) 1163:209-216.
17. NAGASAWA T, KIKUTANI H, KISHIMOTO T: Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc. Natl. Acad. Sci. USA (1994) 91:2305-2309.
18. BLEUL CC, FARZAN M, CHOE H et al.: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (1996) 382:829-833.
19. OBERLIN E, AMARA A, BACHELERIE F et al.: The CXC chemokine SDF-1 is the ligand fbr LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (1996) 382:833-835.
20. TASHIRO K, TADA H, HEILKER R, SHIROZU M, NAKANO T, HONJO T: Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science (1993) 261:600-603.
21. TAMAMURA H, XU Y, HATTORI T et al.: A low molecular weight inhibitor against the chemokine receptor CXCR4: a strong and-HIV peptide T140. Biochem. Biophys. Res. Commun. (1998) 253:877-882.
22. TAMAMURA H, SUGIOKA M, ODAGAKI Y et al.: Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. Bioorg. Med. Chem. Lett. (2001) 11:359-362 & 2409.
23. ICHIYAMA K, HIROSE K, YOKOYAMA S et al.: KRH-1120, a small-CXCR4 antagonistic nonpeptide molecule, with highly potent and selective anti-HIV-1 activity. 13th International AIDS Conference, Durban, South Africa (2000) (Abstract WeOrA535).
24. MACFARLAND RT et al.: An orally bioavailable CXCR4 antagonist for inhibition of HIV replication. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000) (Poster 1845).
25. ENDRES MJ, CLAPHAM PR, MARSH M et al.: CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell (1996) 87:745-756.
26. XU Y, TAMAMURA H, ARAKAKI R et al.: Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. AIDS Res. Hum. Retroviruses (1999) 15:419-427.
27. TAMAMURA H, OMAGARI A, OISHI S et al.: Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg. Med. Chem. Lett. (2000) 10:2633-2637.
28. TAMAMURA H, OMAGARI A, HIRAMATSU K et al.: Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg. Med. Chem. Lett. (2001) 11:1897-1902.
29. 7]-polyphemusin II). Bioorg. Med. Chem. (1998) 6:231-238.
30. TAMAMURA H, ISHIHARA T, OYAKE H et al.: Convenient one-pot synthesis of cystine-containing peptides using the trimethylsilyl chloride-dimethylsulfoxide/trifluoroacetic acid system and its application to the synthesis of bifunctional anti-HIV compounds. J. Chem. Soc. Perkin. Trans. 1 (1998):495-500.
31. TAMAMURA H, OMAGARI A, HIRAMATSU K et al.: Synthesis and evaluation of bifunctional anti-HIV agents based on specific CXCR4 antagonists-AZT conjugation. Bioorg. Med. Chem. (2001) 9:2179-2187.
32. TRKOLA A, DRAGIC T, ARTHOS J et al.: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature (1996) 384:184-187.
33. SCHOLS D, ESTE JA, CABRERA C, DE CLERCQ E: T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1α contains mutations in the envelope gp120, but does not show a switch in coreceptor use. J. Virol. (1998) 72:4032-4037.
34. DE VREESE K, KOFLER-MONGOLD V, LEUTGEB C et al.: The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J. Virol. (1996) 70:689-696.
35. KANBARA K, SATO S, TANUMA J et al.: Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134. AIDS Res. Hum. Retroviruses (2001) 17:615-622.
36. ZHANG W, NAVENOT JM, HARIBABU B et al.: A point mutation that confers constitutive activity to CXCR4 reveals T140 is an inverse agonist and AMD3100 and ALX40-4C are weak partial agonists. J. Biol. Chem. (2002) 277:24515-24521.
37. TAMAMURA H, YAMASHITA M, NAKAJIMA Y et al.: Regiospecific ring-opening reactions of β-aziridinyl α,β-enoates with acids: application to the stereoselective synthesis of a couple of diastereoisomeric (E)-alkene dipeptide isosteres from a single β-aziridinyl α,β-enoate and to the convenient preparation of amino alcohols bearing α,β-unsaturated ester groups. J. Chem. Soc. Perkin. Trans. 1 (1999):2983-2996.
38. TAMAMURA H, HIRAMATSU K, MIYAMOTO K et al.: Synthesis and evaluation of pseudopeptide analogs of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the βII'-turn moiety. Bioorg. Med. Chem. Lett. (2002) 12:923-928.
39. MÜLLER A, HOMEY B, SOTO H et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 410:50-56.
40. KOSHIBA T, HOSOTANI R, MIYAMOTO Y et al.: Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin. Cancer Res. (2000) 6:3530-3535.
41. SEHGAL A, KEENER C, BOYNTON AL, WARRICK J, MURPHY GP: CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J. Surg. Oncol. (1998) 69:99-104.
42. SEHGAL A, RICKS S, BOYNTON AL, WARRICK J, MURPHY GP: Molecular characterization of CXCR-4: a potential brain tumor-associated gene. J. Surg. Oncol, (1998) 69:239-248.
43. REMPEL SA, DUDAS S, GE S, GUTIERREZ JA. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin. Cancer Res. (2000) 6:102-111.
44. GEMINDER H, SAGI-ASSIF O, GOLDBERG L et al.: A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J. Immunol. (2001) 167:4747-4757.
45. OH JW, DRABIK K, KUTSCH O, CHOI C, TOUSSON A, BENVENISTE EN: CXC chemokine receptor 4 expression and function in human astroglioma cells. J. Immunol. (2001) 166:2695-2704.
46. SCOTTON CJ, WILSON JL, MILLIKEN D, STAMP G, BALKWILL FR: Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. (2001) 61:4961-4965.
47. TAICHMAN RS, COOPER C, KELLER ET, PIENTA KJ, TAICHMAN NS, MCCAULEY LK: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. (2002) 62:1832-1837.
48. ROBLEDO MM, BARTOLOME RA, LONGO N et al.: Expression of functional chemokine receptors, CXCR3 and CXCR4 on human melanoma cells. J. Biol. Chem. (2001) 276:45098-45105.
49. SCHRADER AJ, LECHNER O, TEMPLIN M et al.: CXCR4/CXCL12 expression and signalling in kidney cancer. Br. J. Cancer (2002) 86:1250-1256.
50. + hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood (1998) 91:4523-4530.
51. BURGER JA, BURGER M, KIPPS TJ: Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood (1999) 94:3658-3667.
52. MOHLE R, FAILENSCHMID C, BAUTZ F, KANZ L: Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia (1999) 13:1954-1959.
53. MOHLE R, SCHITTENHELM M, FAILENSCHMID C et al.: Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br. J. Haematol. (2000) 110:563-572.
54. DURIG J, SCHMUCKER U, DUHRSEN U: Differential expression of chemokine receptors in B cell malignancies. Leukemia (2001) 15:752-756.
55. CRAZZOLARA R, KRECZY A, MANN G et al.: High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br. J. Haematol. (2001) 115:545-553.
56. BERTOLINI F, DELL'AGNOLA C, MANCUSO P et al.: CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res. (2002) 62:3106-3112.
57. +T cell accumulation in rheumatoid arthritis synovium. J. Immunol. (2000) 165:6590-6598.
58. BABA M, NISHIMURA O, KANZAKI M et al.: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA (1999) 96:5698-5703.
59. MAEDA K, YOSHIMURA K, SHIBAYAMA S et al.: Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J. Biol. Chem. (2001) 276:35194-35200.
60. STRIZKI JM, XU S, WAGNER NE et al.: SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. USA (2001) 98:12718-12723.
61. DORN CP, FINKE PE, OATES B et al.: Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. (2001) 11:259-264.
62. CHAN DC, FASS D, BERGER JM, KIM PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 89:263-273.
63. WILD CT, SHUGARS DC, GREENWELL TK et al.: Peptides corresponding to a predictive alpha-helical domain of human-immunodeficiency-virus type-1 gp41 are potent inhibitors of virus-infection. Proc. Natl. Acad. Sci. USA (1994) 91:9770-9774.
64. KILBY JM: Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors. Expert Opin. Investig. Drugs (1999) 8:1157-1170.
65. OTAKA A, NAKAMURA M, NAMEKI D et al.: Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew Chem. Int. Ed. (2002) 41:2937-2940.